


TABLE OF CONTENTS



Sr. No.	Title	Page No.
Chapter 1	Introduction	
1	General aspects of vitiligo	1
1.1	Historical background	2
1.2	Prevalence	2
1.3	Types of vitiligo	3
1.4	The human skin	5
1.4.1	Melanocytes	6
1.4.2	Melanosomes	8
1.4.3	Melanin	9
1.5	Vitiligo etiopathogenesis	11
1.5.1	Neurochemical Hypothesis	12
1.5.2	Oxidative Stress Hypothesis	16
1.5.2.1	Free radicals	16
1.5.2.2	Reactive Oxygen Species (ROS)	16
1.5.2.3	Reactive Nitrogen Species (RNS)	19
1.5.2.4	ROS in Vitiligo	19
1.5.2.5	Antioxidant defense mechanisms	27
1.5.3	Autoimmune Hypothesis	40
1.5.3.1	Humoral immune response in vitiligo	42
1.5.3.2	Cell mediated immunity:	44
1.5.3.3	Oxidative Stress and the Immune System in Vitiligo Pathogenesis	45
1.5.3.4	Cytokines	49
1.5.3.5	Vitiligo and Apoptosis	59
1.5.4	Convergence Theory	60
1.6	Vitiligo genetics	61
1.7	Single nucleotide polymorphisms	63
1.7.1	SNP analysis	64
1.7.1.1	SNP identification methods	64
1.7.1.2	Snp genotyping methods	66
1.7.2	Association studies	66
1.8	Candidate genes associated with vitiligo susceptibility	67
1.8.1	<i>AIRE</i>	69
1.8.2	<i>CTLA4</i>	69
1.8.3	<i>CAT</i>	69
1.8.4	<i>COMT</i>	69
1.8.5	<i>LMP and TAP</i>	70
1.8.6	<i>MC1R and ASIP</i>	70
1.8.7	<i>ACE</i>	70
1.8.8	<i>ESR1</i>	71
1.8.9	<i>PTPN22</i>	71
1.8.10	<i>KIT</i>	71

1.8.11	<i>FOXD3</i>	72
1.8.12	<i>CD4</i>	72
1.8.13	<i>CLEC11A</i>	72
1.8.14	<i>MYG1 (C12orf10)</i>	73
1.8.15	<i>DDR1</i>	73
1.8.16	<i>EDN1</i>	73
1.8.17	<i>FAS</i>	74
1.8.18	<i>FBXO11-MSH6</i>	74
1.8.19	<i>FOXP3</i>	74
1.8.20	<i>GSTM</i> and <i>GSTT1</i>	74
1.8.21	<i>IL1RN</i>	75
1.8.22	<i>IL10</i>	75
1.8.23	<i>MBL2</i>	75
1.8.24	PDGFRA-Kit	76
1.8.25	<i>TSLP</i>	76
1.8.26	<i>UVRAG</i>	76
1.8.27	<i>VDR</i>	76
1.8.28	<i>XBPI</i>	77
1.9	Linkage and association studies	77
1.9.1	<i>HLA</i> associations	77
1.10	Genome wide association studies	80
1.11	Treatment	82
1.11.1	Non-surgical therapies	82
1.11.2	Surgical therapies	85
1.11.3	Herbal products	87
1.12	References	90
Chapter 2	Role of superoxide dismutase 1 (SOD1) in vitiligo susceptibility	
2.1	Introduction	132
2.2	Materials and methods	134
2.2.1	Study Subjects	134
2.2.2	Blood collection	135
2.2.3	Estimation of LPO levels and SOD1 activity	135
2.2.3.1	Lipid Peroxidation (LPO) levels	136
2.2.3.2	Superoxide Dismutase 1 (SOD1) estimation	137
2.2.4	Determination of <i>SOD1</i> and <i>GAPDH</i> mRNA expression	138
2.2.4.1	RNA extraction and cDNA synthesis	138
2.2.4.2	Real-time PCR	139
2.2.5	Western blot analysis of SOD1 and GAPDH	139
2.2.6	Genomic DNA preparation:	141
2.2.7	Genotyping of <i>SOD1</i> C/T (Ile40Thr) polymorphism	141
2.2.8	High Resolution Melting (HRM) Analysis of <i>SOD1</i> gene	142
2.2.9	Statistical analyses	143
2.3	Results	144
2.3.1	Estimation of lipid peroxidation (LPO) levels in	144

	vitiligo patients and controls	
2.3.2	Estimation of Superoxide Dismutase 1 activity in vitiligo patients and controls	145
2.3.3	Determination of <i>SOD1</i> mRNA and protein levels in vitiligo patients and controls	146
2.3.3.1	Relative gene expression of <i>SOD1</i> in patients with vitiligo and controls	146
2.3.3.2	SOD1 protein levels in patients with vitiligo and controls by western blot analysis	148
2.3.4	Analysis of association between <i>SOD1</i> exon 2 C/T (Ile40Thr) polymorphism and susceptibility to vitiligo	150
2.3.5	<i>SOD1</i> gene scanning for novel genetic variations using High Resolution Melt Curve (HRM) analysis	151
2.4	Discussion	155
2.5	References	159
Chapter 3	Role of superoxide dismutase 2 (SOD2) in vitiligo susceptibility	
3.1	Introduction	162
3.2	Materials and methods	165
3.2.1	Study Subjects	165
3.2.2	Blood collection and genomic DNA preparation	166
3.2.3	Genotyping of <i>SOD2</i> Leu84Phe (C/T) and Thr58Ile (C/T) polymorphisms	166
3.2.4	Genotyping of <i>SOD2</i> Val16Ala (T/C) and Ile82Thr (T/C) polymorphisms	167
3.2.5	Estimation of Superoxide dismutase 2 activity	168
3.2.6	Determination of <i>SOD2</i> and <i>GAPDH</i> mRNA expression	170
3.2.6.1	RNA extraction and cDNA synthesis	170
3.2.6.2	Real-time PCR	170
3.2.7	Statistical analyses	171
3.3	Results	172
3.3.1	Analysis of association between <i>SOD2</i> C/T; Leu84Phe polymorphism and susceptibility to vitiligo	172
3.3.2	Analysis of association between <i>SOD2</i> C/T; Thr58Ile polymorphism and susceptibility to vitiligo	173
3.3.3	Analysis of association between <i>SOD2</i> T/C; Val16Ala polymorphism and susceptibility to vitiligo	175
3.3.4	Analysis of association between <i>SOD2</i> T/C; Ile82Thr polymorphism and susceptibility to vitiligo	176
3.3.5	Relative gene expression of <i>SOD2</i> in patients with vitiligo and controls	182
3.3.6	Estimation of SOD2 activity in vitiligo patients and controls	183

3.3.7	Correlation of <i>SOD2</i> C/T (Leu84Phe), C/T (Thr58Ile) and T/C (Val16Ala) genotypes with <i>SOD2</i> activity in vitiligo patients	184
3.4	Discussion	186
3.5	References	192
Chapter 4	Role of superoxide dismutase 3 (SOD3) in vitiligo susceptibility	
4.1	Introduction	197
4.2	Materials and methods	200
4.2.1	Study Subjects	200
4.2.2	Blood collection and genomic DNA Preparation	201
4.2.3	Genotyping of <i>SOD3</i> Arg213Gly (C/G) and Ala40Thr (G/A) polymorphisms	202
4.2.4	Estimation of Superoxide dismutase 3 activity	203
4.2.5	Determination of <i>SOD3</i> and <i>GAPDH</i> mRNA expression	204
4.2.6	Statistical analyses	205
4.3	Results	206
4.3.1	Analysis of association between <i>SOD3</i> C/G; Arg213Gly polymorphism and susceptibility to vitiligo	206
4.3.2	Analysis of association between <i>SOD3</i> G/A; Ala40Thr polymorphism and susceptibility to vitiligo	207
4.3.3	Relative gene expression of <i>SOD3</i> in patients with vitiligo and controls	212
4.3.4	Estimation of <i>SOD3</i> activity in vitiligo patients and controls	213
4.3.5	Correlation of <i>SOD3</i> C/G (Arg213Gly) and G/A (Ala40Thr) genotypes with <i>SOD3</i> activity in vitiligo patients	214
4.4	Discussion	216
4.5	References	220
Chapter 5	Evaluation of oxidative stress and autoimmune hypotheses in onset and progression of vitiligo	
5.1	Introduction	224
5.2	Materials and methods	224
5.2.1	Study subjects	224
5.2.2	Estimation of lipid peroxidation (LPO) levels	225
5.2.3	Estimation of antimelanocyte antibody levels by enzyme linked immunosorbent assay (ELISA)	226
5.2.4	Statistical analysis	226
5.3	Results	227
5.4	Discussion	229
5.5	References	231
Chapter 6	Role of tumor necrosis factor α (TNFα) in vitiligo susceptibility	
6.1	Introduction	232

6.2	Materials and methods	234
6.2.1	Study Subjects	234
6.2.2	Blood collection and DNA extraction	234
6.2.3	Genotyping of <i>TNFA</i> promoter polymorphisms	235
6.2.4	Determination of <i>TNFA</i> , <i>ICAM1</i> and <i>GAPDH</i> mRNA expression	236
6.2.4.1	RNA extraction and cDNA synthesis	236
6.2.4.2	Real-time PCR	236
6.2.5	Estimation of serum TNF α levels by enzyme-linked immunosorbent assay	239
6.2.6	Statistical analyses	239
6.3	Results	240
6.3.1	Association of <i>TNFA</i> promoter polymorphisms with generalized vitiligo	240
6.3.2	Association of <i>TNFA</i> promoter polymorphisms with localized vitiligo	243
6.3.3	Linkage disequilibrium (LD) and haplotype analyses of <i>TNFA</i> promoter polymorphisms	245
6.3.4	Age of onset of vitiligo and <i>TNFA</i> promoter haplotypes in patients with vitiligo	250
6.3.5	Relative gene expression of <i>TNFA</i> in patients with vitiligo and controls	251
6.3.6	Functional correlation of <i>TNFA</i> promoter polymorphisms with its levels in the serum	253
6.3.7	Relative gene expression of <i>ICAM1</i> in patients with vitiligo and controls	255
6.4	Discussion	258
6.5	References	264
Chapter 7	Role of tumor necrosis factor-β (TNFβ) in vitiligo susceptibility	
7.1	Introduction	269
7.2	Materials and methods	271
7.2.1	Study Subjects	271
7.2.2	Genomic DNA preparation	272
7.2.3	Genotyping of <i>TNFB</i> +252G/A polymorphism	272
7.2.4	Genotyping of <i>TNFB</i> Thr26Asn A/C polymorphism	273
7.2.5	Determination of <i>TNFB</i> and <i>GAPDH</i> mRNA expression	274
7.2.5.1	RNA extraction and cDNA synthesis	274
7.2.5.2	Real-time PCR	274
7.2.6	Statistical analyses	274
7.3	Results	275
7.3.1	Analysis of association between <i>TNFB</i> +252G/A polymorphism and susceptibility to vitiligo	275
7.3.2	Analysis of association between <i>TNFB</i> A/C; Thr26Asn polymorphism and susceptibility to vitiligo	279
7.3.3	Effect of <i>TNFB</i> +252G/A genotypes on age of	282

	onset of vitiligo and its progression	
7.3.4	Linkage disequilibrium (LD) and haplotype analyses	285
7.3.5	Relative gene expression of <i>TNFB</i> in patients with vitiligo and controls	285
7.3.6	Correlation of <i>TNFB</i> transcripts with the <i>TNFB</i> +252G/A genotypes	286
7.3.7	Correlation of <i>TNFB</i> transcripts with the <i>TNFB</i> A/C genotypes	286
7.3.8	Effect of <i>TNFB</i> expression on disease progression	286
7.4	Discussion	290
7.5	References	295
	Concluding Remarks	306
	Appendix	
	Publications and Presentations	
	Synopsis	